Revenue Growth Boosters:
The global in situ hybridization market size is projected to reach USD 1.3 billion by 2025 from USD 0.9 billion in 2020, at a CAGR of 7.4% during the forecast period. The increasing incidence of cancer and genetic disorder and awareness of ISH based companion diagnostics tests are the major factors driving the growth of this market.
Overview of This Research:
This market research study involved the extensive use of secondary sources, directories, and databases to identify and collect information useful for this technical, market-oriented, and financial study of the global in situ hybridization market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify critical qualitative and quantitative information and to assess market prospects. The size of the ISH market was estimated through various secondary research approaches and triangulated with inputs from primary research to arrive at the final market size.
Download PDF Brochure@
The cancer diagnostic segment accounted for the largest share of the application segment in the in situ hybridization market
Based on the application, the in situ hybridization market is segmented broadly into cancer diagnostics, cytology, infectious disease diagnostics, neuroscience, and immunology. The cancer diagnostics segment accounted for the largest share of the global market. This can be attributed to the high demand of FISH in the detection of cellular and genetic markers in cancers such as HER2, ALK, and ROS.
Hospitals & diagnostic laboratories accounted for the fastest-growing end user segment of the in situ hybridization market
Based on the end user, the in situ hybridization market is segmented into hospital & diagnostic laboratories, academic & research institutes, CROs, and pharmaceutical & biotechnology companies. The hospital & diagnostic laboratories segment accounted for the largest share of the ISH market in 2019. This can be attributed to the increasing number of molecule-based screening, increasing number of specialty diagnostic tests performed in hospital laboratories, the rising number of in-house diagnostic procedures, and the rising trend of establishing in-house diagnostic capabilities in hospitals.
North America accounted for the largest share of the in situ hybridization market
North America accounted for the largest share of the global market, followed by Europe. The large share of the North American region can be attributed to the presence of major players operating in the in situ hybridization market in the US, the rising incidence of cancer and infectious diseases, and the increasing adoption of CDx assay kits.
The prominent players operating in the in situ hybridization market are Abbott Laboratories (US), F. Hoffmann-La Roche Ltd (Switzerland), Agilent Technologies, Inc. (US), and Danaher Corporation (US).
Request Sample Pages@
Market Size Estimation:
The global size of the in situ hybridization market was estimated through multiple approaches. A detailed market estimation approach was followed to estimate and validate the value of the global ISH market and other dependent submarkets.. The research methodology and the market numbers were then validated from primaries.
After arriving at the overall market size, from the market size estimation process explained above, the in situ hybridization market was split into segments and subsegments. To complete the overall market engineering process and to arrive at the exact statistics for all segments and subsegments, the data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides in the ISH market.